ID | 53675 |
JaLCDOI | |
フルテキストURL | |
著者 |
Sugiu, Kumi
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Iwamoto, Takayuki
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Kaken ID
researchmap
Kelly, Catherine M.
Department of Oncology, Mater Misericordiae University Hospital
Watanabe, Naoki
Department of Surgery, Chugoku Central Hospital
Motoki, Takayuki
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
publons
Itoh, Mitsuya
Department of Breast Surgery, Hiroshima City Hospital
Ohtani, Shoichiro
Department of Breast Surgery, Hiroshima City Hospita
Higaki, Kenji
Department of Breast Surgery, Hiroshima City Hospital
Imada, Takako
Department of Surgery, Okayama Central Hospital
Yuasa, Takeshi
Department of Surgery, Himeji Red Cross Hospital
Omori, Masako
Department of Pathology, Okayama University Hospital
Sonobe, Hiroshi
Department of Pathology, Chugoku Central Hospital
Fujiwara, Toshiyoshi
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
ORCID
Kaken ID
publons
researchmap
Matsuoka, Junji
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science b Department of Breast and Endocrine Surgery, Okayama University Hospital
Kaken ID
researchmap
|
抄録 | Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%;2/16) and the chemotherapy alone group (8.3%;1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (p=0.035), but not in the chemotherapy-alone group (p=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies.
|
キーワード | breast cancer
neoadjuvant chemotherapy
concurrent hormone therapy
estrogen receptor positive
tumor response
|
Amo Type | Original Article
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2015-10
|
巻 | 69巻
|
号 | 5号
|
出版者 | Okayama University Medical School
|
開始ページ | 291
|
終了ページ | 299
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | CopyrightⒸ 2015 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID | |
Web of Science KeyUT |